Qu Y, Xu J, Jiang T, Zhao H, Gao Y, Zheng C, Shi X
Department of Orthopaedics, Changzhou Traditional Chinese Medical Hospital, affiliated to Nanjing University of Traditional Chinese Medicine, Changzhou, China.
J Int Med Res. 2011;39(4):1474-82. doi: 10.1177/147323001103900436.
This retrospective analysis examined the difference in pre- and postchemotherapy levels of vascular endothelial growth factor (VEGF) as an indicator of osteosarcoma prognosis. VEGF protein levels were assessed immunohistochemically in primary tumour samples from 61 osteosarcoma patients diagnosed between February 2001 and July 2005. The difference in pre- and postchemotherapy VEGF protein reduction levels was categorized into weak (23 patients) and strong (38 patients). The 5-year survival rate was significantly lower in the weak VEGF reduction group (34.8%) than in the strong VEGF reduction group (73.7%). The weak VEGF reduction group had significantly higher rates of metastasis and recurrence. Multivariate analysis confirmed that the change in VEGF was an independent and significant factor for predicting a good prognosis. The analysis of VEGF will enable clinicians to tailor surgery and chemotherapy regimens more appropriately, earlier in the disease process.
这项回顾性分析研究了化疗前后血管内皮生长因子（VEGF）水平的差异，以此作为骨肉瘤预后的一个指标。对2001年2月至2005年7月期间确诊的61例骨肉瘤患者的原发肿瘤样本进行免疫组织化学评估VEGF蛋白水平。化疗前后VEGF蛋白降低水平的差异分为降低程度弱（23例患者）和降低程度强（38例患者）。VEGF降低程度弱的组5年生存率（34.8%）显著低于VEGF降低程度强的组（73.7%）。VEGF降低程度弱的组转移和复发率显著更高。多因素分析证实，VEGF的变化是预测良好预后的一个独立且显著的因素。对VEGF的分析将使临床医生能够在疾病进程的早期更恰当地调整手术和化疗方案。
Zotero 插件